LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

Search

Allogene Therapeutics Inc

Chiusa

SettoreSettore sanitario

1.17 -1.68

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

1.17

Massimo

1.22

Metriche Chiave

By Trading Economics

Entrata

206K

-60M

EPS

-0.28

Margine di Profitto

272,450

Dipendenti

226

EBITDA

-302K

-56M

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+631.67% upside

Dividendi

By Dow Jones

Utili prossimi

6 ago 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

11M

267M

Apertura precedente

2.85

Chiusura precedente

1.17

Notizie sul Sentiment di mercato

By Acuity

100%

0%

364 / 380 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Very Strong Bearish Evidence

Allogene Therapeutics Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

27 giu 2025, 20:51 UTC

Utili

These Stocks Moved the Most Today: Nike, Nvidia, Coinbase, Palantir, Boeing, Newmont, Core Scientific, and More -- Barrons.com

27 giu 2025, 20:50 UTC

Discorsi di Mercato

Tech, Media & Telecom Roundup: Market Talk

27 giu 2025, 20:50 UTC

Discorsi di Mercato

Financial Services Roundup: Market Talk

27 giu 2025, 20:48 UTC

Discorsi di Mercato

Computer Lobby Cheers Move to Punish Canada Over Digital Tax -- Market Talk

27 giu 2025, 20:46 UTC

Discorsi di Mercato

Market Talk Roundup: Latest on U.S. Politics

27 giu 2025, 20:46 UTC

Discorsi di Mercato

Canada Dismissal of Risk From Digital Tax Is 'Shocking' -- Market Talk

27 giu 2025, 19:31 UTC

Discorsi di Mercato

Canada CEOs Call for Carney to Drop Digital Tax -- Market Talk

27 giu 2025, 19:19 UTC

Discorsi di Mercato

Oil Posts Weekly Loss As Geopolitical Premium Evaporates -- Market Talk

27 giu 2025, 19:16 UTC

Discorsi di Mercato

U.S. Natural Gas Futures Snap Losing Streak -- Market Talk

27 giu 2025, 18:57 UTC

Acquisizioni, Fusioni, Takeovers

Russian Oligarch Roman Abramovich Is Evraz PLC's Largest Shareholder With 29% Stake -- WSJ

27 giu 2025, 18:57 UTC

Acquisizioni, Fusioni, Takeovers

Evraz North America Parent Evraz PLC Remains Under Sanction by U.K. -- WSJ

27 giu 2025, 18:57 UTC

Acquisizioni, Fusioni, Takeovers

Evraz North America Employs About 3,400 People, Has 3.5 Million Tons of Finished Steel Capacity -- WSJ

27 giu 2025, 18:57 UTC

Acquisizioni, Fusioni, Takeovers

Atlas Holdings to Buy Evraz North America for Up to $500 Million, Companies Say -- WSJ

27 giu 2025, 18:57 UTC

Acquisizioni, Fusioni, Takeovers

Atlas Holdings to Buy Evraz North America for Up to $500 Million, Companies Say -- WSJ

27 giu 2025, 18:42 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

27 giu 2025, 18:42 UTC

Discorsi di Mercato

Canada's Carney 'Likely Amenable' to Dropping Digital-Services Tax -- Market Talk

27 giu 2025, 18:39 UTC

Discorsi di Mercato
Utili

Nike's Second-Half Prospects Can Get Better as Worst is Behind it -- Market Talk

27 giu 2025, 18:29 UTC

Discorsi di Mercato

Canada Recession Risks Likely to Rise With Trump's Termination of Tariff Talks -- Market Talk

27 giu 2025, 18:18 UTC

Discorsi di Mercato

Canadian Dollar Sharply Weakens on Trump's Surprise End to US-Canada Tariff Talks -- Market Talk

27 giu 2025, 18:16 UTC

Discorsi di Mercato

Trump's Threat Against Canada Weighs Down Treasurys -- Market Talk

27 giu 2025, 17:16 UTC

Discorsi di Mercato

U.S. Oil Rig Count Falls by 6 to 432 -- Market Talk

27 giu 2025, 17:08 UTC

Utili

McDonald's Stock Has Slipped. One Analyst Sees 21% Upside. -- Barrons.com

27 giu 2025, 16:52 UTC

Acquisizioni, Fusioni, Takeovers

Nike Stock Soars After Earnings. Is It Time to Just Buy It? -- Barrons.com

27 giu 2025, 16:22 UTC

Utili

These Stocks Are Moving the Most Today: Nike, Nvidia, Coinbase, Palantir, Boeing, Newmont, Core Scientific, and More -- Barrons.com

27 giu 2025, 16:20 UTC

Discorsi di Mercato

Financial Services Roundup: Market Talk

27 giu 2025, 16:20 UTC

Discorsi di Mercato

Tech, Media & Telecom Roundup: Market Talk

27 giu 2025, 16:20 UTC

Discorsi di Mercato

Auto & Transport Roundup: Market Talk

27 giu 2025, 16:15 UTC

Discorsi di Mercato

Global Commodities Roundup: Market Talk

27 giu 2025, 15:59 UTC

Discorsi di Mercato

Gold Futures Slump on Improving Risk Appetite -- Market Talk

27 giu 2025, 15:56 UTC

Discorsi di Mercato

Nvidia Again Helping To Power New S&P Highs -- Market Talk

Confronto tra pari

Modifica del prezzo

Allogene Therapeutics Inc Previsione

Obiettivo di Prezzo

By TipRanks

631.67% in crescita

Previsioni per 12 mesi

Media 8.78 USD  631.67%

Alto 14 USD

Basso 4 USD

Basato su 13 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Allogene Therapeutics Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

13 ratings

11

Acquista

2

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

1.18 / 1.69Supporto e resistenza

A breve termine

Very Strong Bearish Evidence

A termine intermedio

Weak Bullish Evidence

A lungo termine

Weak Bearish Evidence

Sentiment

By Acuity

364 / 380 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove ribassiste molto forti

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Allogene Therapeutics Inc

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.